The UK has made progress in its efforts to slash set-up times for clinical trials, one of the factors blamed for a decline in industry-backed studies.
AbbVie’s Skyrizi narrowly slides ahead of J&J’s Tremfya in May drug ad spending rankings
May saw a drug ad spending slump across the majority of the top ten drug ad spenders with AbbVie’s Skyrizi and RInvoq, Johnson & Johnson’s
